Please provide your email address to receive an email when new articles are posted on . The FDA expanded Spevigo’s approval to include children aged 12 years and older weighing 40 kg or more. The ...
Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...
Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...
Scalp folliculitis is a skin condition that occurs when the hair follicles on the scalp become inflamed. This results in pustules, whiteheads, or other pimple-like bumps on the scalp that can be ...
The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...
Vanda Pharmaceuticals and AnaptysBio have announced a global license agreement for the development and commercialization of imsidolimab, an IL-36R antagonist that has completed two successful Phase 3 ...
Folliculitis is a common skin condition that occurs when hair follicles become inflamed due to infection, irritation, or blockage. The most frequent cause is a bacterial infection, though fungi and ...
A 5-day-old female is transferred from another hospital due to irritability and a worsening pustular rash. The mother’s pregnancy, labor and delivery was complicated by a group B strep-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results